The 2026 FDA Peptide Reclassification: What Changed and What It Means for Patients
In early 2026, the FDA reversed a sweeping 2023 decision that had placed many popular peptides off-limits for compounding pharmacies, cutting off access to therapies that thousands of patients had been using under medical supervision. Fourteen of nineteen restricted peptides were reclassified back to Category 1, which means they can
